The Gemini Brief- Investment Deep Dives

Comprehensive Equity Analysis: Roche Holding AG (ROG.SW) – Navigating a Strategic Inflection Point

All investment deep dives on this site have been written by Google Gemini with light human editing. Nothing on this site constitutes investment advise. All materials on this site are for informational purposes only.

The Gemini Brief - Investment Deep Dives
The Gemini Brief – Investment Deep Dives
Comprehensive Equity Analysis: Roche Holding AG (ROG.SW) – Navigating a Strategic Inflection Point
Loading
/

Executive Summary

This report provides a comprehensive analysis of Roche Holding AG (Roche), a global leader in pharmaceuticals and diagnostics, to support informed investment decision-making. The analysis indicates that Roche is at a pivotal strategic inflection point. Having successfully navigated the dual headwinds of a significant patent cliff for its legacy oncology blockbusters and the sharp normalization of its pandemic-driven diagnostics revenue, the company has demonstrated the resilience of its integrated business model. The robust growth of a newer portfolio of innovative medicines, particularly in neuroscience, ophthalmology, and haematology, has more than compensated for these revenue gaps, returning the Group to solid growth in 2024.

Financially, Roche is characterized by its formidable cash flow generation, which underpins a substantial research and development budget and a long-standing commitment to annual dividend increases. Recent strategic activity, including a series of bolt-on acquisitions in high-growth fields like immunology and obesity, signals a clear intent to secure future growth drivers and replenish the pipeline for the long term.

The core analytical focus now shifts from near-term survival of patent expiries to the long-term sustainability of its growth trajectory. Key questions revolve around the ability of the current late-stage pipeline to deliver the next wave of blockbusters, the company’s capacity to defend its market share against increasingly sophisticated competition, and its vulnerability to global healthcare pricing pressures, particularly in the concentrated U.S. market. This report dissects Roche’s operational segments, competitive standing, financial health, and strategic direction to provide a holistic view of its prospects and challenges through 2025 and beyond.

1. Company Overview & Business Model

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, operating globally under two primary divisions: Pharmaceuticals and Diagnostics.1 The company’s core strategic principle is “Personalised Healthcare,” which leverages the unique synergy between its two divisions. This integrated approach aims to develop targeted therapies by using advanced diagnostics to identify the patients most likely to benefit, creating a powerful feedback loop between diagnosis and treatment that serves as a key differentiator in the industry.1

Core Business Segments and Revenue Breakdown

Roche’s business is structured around its two powerful, market-leading segments. The dynamic between these divisions was particularly evident in 2023 and 2024 as the company managed significant market shifts.

  • 2023 Performance: The Group reported total sales of CHF 58.7 billion, a modest increase of 1% at constant exchange rates (CER). This headline figure masked divergent divisional performances. The Pharmaceuticals Division was the engine of growth, with sales rising 6% (CER) to CHF 44.6 billion, driven by strong uptake of newer medicines. In contrast, the Diagnostics Division saw sales fall sharply by 13% (CER) to CHF 14.1 billion, a direct consequence of the anticipated collapse in demand for COVID-19 tests following the pandemic’s official end.3
  • 2024 Performance: The Group demonstrated a significant acceleration, with sales growing 7% (CER) to CHF 60.5 billion. This was fueled by continued strength in the Pharmaceuticals Division, which grew 8% (CER) to CHF 46.2 billion. Crucially, the Diagnostics Division returned to growth, with sales increasing 4% (CER) to CHF 14.3 billion. The underlying base business (excluding COVID-19 products) in diagnostics showed robust health, growing 8% (CER) for the year, signaling a successful post-pandemic normalization.5

Geographic Revenue Distribution and Market Exposure

Roche’s sales are globally distributed but show a significant concentration in the U.S. market, particularly for its high-value pharmaceuticals.

  • Pharmaceuticals Division (FY 2024): The United States is the single most important market, accounting for 53.7% of divisional sales. This is followed by Europe (19.1%), the International region (which includes China, Canada, and Brazil) at 21.0%, and Japan at 6.2%.6 This heavy reliance on the U.S. has been a source of high-margin growth but now represents a significant concentration risk amid intensifying pricing pressures in that market.
  • Diagnostics Division: The division has a more balanced geographic footprint. However, recent results highlight regional vulnerabilities. In the first half of 2025, sales in the EMEA and North American regions grew by 5% and 6% respectively, while sales in the Asia-Pacific region declined by 15%, primarily due to healthcare pricing reforms in China.8

Key Therapeutic Areas and Diagnostic Platforms

Pharmaceuticals Franchise: Roche’s portfolio is focused on areas of high unmet medical need. The primary therapeutic areas are Oncology, Neuroscience, Immunology, Ophthalmology, and Haematology.10 The company’s revenue base has successfully transitioned from its legacy oncology trio (Avastin, Herceptin, Rituxan), which collectively saw sales fall by 22% in 2023 due to biosimilar competition.12 Growth is now powered by a new cohort of blockbuster and high-growth products. In 2024, the top four growth drivers alone—Vabysmo, Phesgo, Ocrevus, and Hemlibra—generated CHF 16.9 billion in sales.7

  • Ocrevus (Neuroscience): A leading treatment for multiple sclerosis, with 2024 sales of CHF 6.7 billion (+9% CER).7
  • Hemlibra (Haematology): A transformative therapy for haemophilia A, with 2024 sales of CHF 4.5 billion (+12% CER).7
  • Vabysmo (Ophthalmology): A new bispecific antibody for severe eye diseases, demonstrating explosive growth with 2024 sales reaching CHF 3.9 billion (+68% CER).7
  • Tecentriq (Oncology): A foundational cancer immunotherapy, with stable sales of CHF 3.6 billion in 2024.7
  • Phesgo (Oncology): A convenient subcutaneous combination of Perjeta and Herceptin for breast cancer, with sales surging 62% in 2024 to CHF 1.7 billion.7

Diagnostics Franchise: As the global leader in in-vitro diagnostics (IVD), Roche operates across four main customer areas 13:

  • Core Lab: High-throughput systems for clinical chemistry and immunodiagnostics, forming the backbone of hospital laboratories.
  • Molecular Lab: Platforms like the cobas 6800/8800 systems for virology, blood screening, and infectious diseases.
  • Pathology Lab: A market-leading position in tissue-based cancer diagnostics and advanced staining.
  • Point of Care: Solutions for rapid testing in settings like emergency rooms and clinics.
    This division’s strength is built on the world’s largest installed base of over 100,000 diagnostic platforms, which creates a significant recurring revenue stream from the sale of proprietary reagents and consumables.14

Business Model Characteristics

The combination of these two divisions creates a business model with distinct and advantageous characteristics:

  • Synergistic Integration: The ability to develop a diagnostic test alongside a targeted drug (companion diagnostics) is a core strategic advantage. This allows Roche to identify specific patient populations, improve clinical trial success rates, and secure market access for its high-value medicines.
  • Resilience and Stability: The Diagnostics division provides a stable and predictable foundation of recurring revenue that helps to smooth the volatility inherent in the patent-driven, blockbuster-cycle nature of the Pharmaceuticals business.
  • Innovation-Driven Pricing Power: Roche’s focus on developing first-in-class or best-in-class treatments for severe diseases has historically afforded it significant pricing power. However, this is facing increasing pressure from global healthcare reforms.15

The financial results from 2023 and 2024 clearly demonstrate that the growth from Roche’s new pharmaceutical portfolio has successfully bridged the revenue gap created by the dual pressures of the COVID-19 diagnostics cliff and the biosimilar erosion of its legacy cancer drugs. The primary risk facing the company from 2022 to 2024 was whether this transition could be executed without a significant drop in overall revenue. The 7% group sales growth in 2024, with the base business excluding COVID-19 products growing at 9%, confirms that management has effectively navigated this challenge.4 This success de-risks the company’s near-term financial profile and validates the R&D strategy of the past decade. The analytical focus thus shifts from a question of survival to one of sustainability.

2. Industry Context & Dynamics

Roche operates within the global life sciences industry, a vast ecosystem that is undergoing profound structural and technological shifts. The company’s performance and strategic decisions are heavily influenced by the distinct dynamics of the pharmaceutical and diagnostics markets.

Global Pharmaceutical Industry Trends and Outlook

The global pharmaceutical market, which accounts for approximately 70% of the ~$1.9 trillion life sciences industry, is projected to grow at a compound annual growth rate (CAGR) of 6-7% through 2028.16 This growth is underpinned by powerful secular trends, including aging populations in developed nations, the rising prevalence of chronic diseases globally, and continuous scientific advances in emerging therapeutic modalities like cell and gene therapies, antibody-drug conjugates (ADCs), and radioligand therapies.16 Key therapeutic areas expected to drive this growth are oncology, immunology, and the rapidly expanding markets for diabetes and obesity treatments.16

However, the industry is also navigating significant headwinds that are reshaping its operational and economic models:

  • The Rise of Artificial Intelligence (AI): AI and machine learning are poised to revolutionize drug discovery and development. Projections suggest that by 2025, 30% of new drugs will be discovered using AI, which has the potential to reduce preclinical timelines and costs by 25-50%.18 This technological shift could significantly enhance R&D productivity but also lower barriers to entry, potentially intensifying competition.
  • Intensifying Pricing Pressure: Governments and payers globally are implementing stricter cost-containment measures. In the United States, Roche’s largest market, the Inflation Reduction Act (IRA) has introduced direct government price negotiation for certain high-expenditure drugs, fundamentally challenging the industry’s long-standing pricing power.15
  • Strategic M&A: Following a period of moderation, biopharma M&A activity is expected to accelerate into 2025. Large pharmaceutical companies with strong balance sheets are actively seeking to acquire or license late-stage assets from smaller biotech firms to replenish their pipelines and address upcoming patent expiries.16

Diagnostics Market Evolution and Growth Drivers

The global in-vitro diagnostics (IVD) market, estimated at approximately $106 billion in 2024, is forecast to grow at a CAGR of around 4.1% to reach over $155 billion by 2034.19 This steady growth is propelled by several key factors:

  • Disease Burden: The increasing incidence of infectious diseases and chronic conditions like cancer and diabetes necessitates more frequent and accurate diagnostic testing.19
  • Personalized Medicine: The shift towards tailored treatments requires sophisticated diagnostic tools, particularly in molecular diagnostics and genomics, to stratify patients and guide therapy selection.19
  • Decentralization of Care: There is a growing adoption of point-of-care testing (POCT), which brings diagnostic capabilities closer to the patient in clinics, pharmacies, and even at home, enabling faster clinical decisions.22

    Technological advancements in lab automation, AI-powered data analysis, and the miniaturization of testing platforms are further transforming the diagnostics landscape.20

Patent Cliff Dynamics and Biosimilar Competition

The pharmaceutical industry is contending with one of its most significant structural challenges: the “patent cliff.” An estimated $200 billion in branded drug revenue is at risk from patent expirations in the coming years.16 The entry of biosimilars—highly similar, lower-cost versions of biologic drugs—is fundamentally altering market dynamics.24

  • Accelerated Market Penetration: Unlike the early days of biosimilars, market uptake is now faster and deeper. In the U.S., recently launched oncology biosimilars captured nearly 50% of the market volume within their first year, a rate even faster than in Europe.25 The introduction of competition has been shown to reduce the average sales price of both the reference product and the biosimilar, generating significant healthcare system savings.26
  • Strategic Innovator Response: The certainty of a finite period of market exclusivity has created an “innovation squeeze” on originator companies.24 This forces a polarization of R&D strategy. On one hand, companies must invest in higher-risk, truly novel, first-in-class therapies where scientific differentiation is clear. On the other hand, it incentivizes the development of “bio-betters”—next-generation versions of existing drugs with demonstrable improvements, such as enhanced efficacy or a more convenient route of administration (e.g., subcutaneous injection instead of intravenous infusion).24

This dynamic of proactive lifecycle management is becoming a critical competency. Roche’s development of Phesgo, a fixed-dose subcutaneous combination of its established breast cancer drugs Perjeta and Herceptin, serves as a prime example. This strategy aims to transition the market to a new, more convenient, and patent-protected product before biosimilars of the individual intravenous components can gain a significant foothold. The explosive sales growth of Phesgo represents a planned, controlled cannibalization of older products, effectively defending the franchise. The development of a subcutaneous formulation of Ocrevus suggests this is a core and repeatable strategy for the company.5

3. Competitive Positioning

Roche maintains a formidable competitive position, anchored by its dual leadership in the global oncology and in-vitro diagnostics markets. Its integrated business model and sustained investment in innovation have created durable competitive advantages, though it faces intense pressure from established peers and emerging challengers across all its key business areas.

Market Share Analysis

Roche’s leadership is evident in its market share in key segments:

  • Diagnostics: Roche is the undisputed global leader in the in-vitro diagnostics (IVD) market, holding a commanding share of approximately 19-20%.2 This places it significantly ahead of its main competitors, including Abbott Laboratories, Danaher, and Siemens Healthineers.
  • Oncology: Historically, Roche has been the dominant force in oncology therapeutics, with a market share of around 30%.2 While this leadership has been challenged by the rise of immuno-oncology competitors and the biosimilar erosion of its legacy blockbusters, the company maintains one of the most comprehensive and powerful oncology portfolios in the industry.11
  • Key Product Franchises: The company holds leading or rapidly growing market share in several critical therapeutic areas:
  • Multiple Sclerosis (MS): Ocrevus is the dominant therapy in the MS market, commanding an estimated 38% market share by value, a position strengthened by its unique approval for both relapsing and primary progressive forms of the disease.28 It has a patient share of approximately 24% across the U.S. and the five largest European markets.29
  • Haemophilia A: Since its launch, Hemlibra has transformed the treatment paradigm and has become the most prescribed prophylactic therapy, rapidly displacing older, inconvenient intravenous factor replacement treatments.30
  • Ophthalmology: Vabysmo has mounted a highly successful challenge to Regeneron’s long-dominant Eylea. As of the first quarter of 2024, Vabysmo had already captured a 25% market share in neovascular age-related macular degeneration (nAMD) and an 18% share in diabetic macular edema (DME) in the crucial U.S. market.32

Competitive Advantages and Moats

Roche’s competitive strengths are multifaceted and deeply embedded in its corporate structure and strategy:

  • Innovation Engine: Sustained, large-scale investment in research and development is the cornerstone of Roche’s moat. With an R&D budget of CHF 13.2 billion in 2023, the company has the resources to pursue high-risk, high-reward science across a broad range of diseases and modalities.3
  • Integrated “Pharma + Diagnostics” Model: This is Roche’s most unique and durable competitive advantage. The ability to develop and commercialize a diagnostic test that identifies the precise patient population for a targeted Roche drug creates a powerful, self-reinforcing ecosystem. This synergy enhances R&D productivity, improves clinical outcomes, and erects significant barriers to entry for competitors that lack capabilities in both areas.1
  • Expertise in Biologics: Approximately three-quarters of Roche’s pharmaceutical sales are derived from biologics.2 These complex, large-molecule drugs are inherently more difficult and costly to manufacture and replicate than traditional small-molecule chemical drugs, providing a natural buffer against generic competition even after patent expiry.
  • Global Commercial Scale: A deeply entrenched global sales, marketing, and distribution infrastructure enables Roche to execute highly effective product launches and achieve rapid market penetration for its new medicines and diagnostic platforms worldwide.

Key Competitors and Threats

Roche competes against a formidable set of peers in both of its divisions:

  • Pharmaceuticals: Its primary competitors are other large, research-driven pharmaceutical companies, including Novartis, Johnson & Johnson, Merck, Pfizer, AbbVie, and AstraZeneca.33 Competition is particularly intense in oncology, where Merck’s Keytruda has become a dominant force in immuno-oncology, and in immunology, where numerous players are vying for market share.
  • Diagnostics: The main competitors are large, diversified healthcare technology companies such as Abbott Laboratories, Danaher Corporation, and Siemens Healthineers. Competition in this segment is driven by instrument performance, automation, breadth of the test menu, and increasingly, data management and software solutions.35
  • Emerging Threats: The competitive landscape is being reshaped by two key forces. First, the rise of highly focused and agile biotechnology companies, which are responsible for a growing share of industry innovation. Second, the increasing prowess of biosimilar manufacturers like Sandoz and Amgen, which pose a direct and significant threat to the revenue streams of Roche’s legacy biologic products.24

Differentiation Factors

Roche differentiates itself through a clear focus on science-led innovation and the strategic advantages of its integrated model.

  • Pharmaceuticals: The company seeks to differentiate its products by targeting novel biological pathways (e.g., Vabysmo’s dual-action mechanism) and by creating “bio-betters” that offer superior patient convenience and clinical value, such as the subcutaneous formulation of Ocrevus or the combined Phesgo injection.5
  • Diagnostics: Differentiation is achieved through the industry’s most comprehensive test portfolio, the reliability and efficiency of its high-throughput platforms (e.g., the cobas family), and its leadership in high-value areas like tissue diagnostics, liquid biopsy (via its Foundation Medicine subsidiary), and digital pathology solutions.13

The company’s competitive moat is evolving. Historically built on the strength of individual blockbuster drugs, it is now shifting towards establishing platform dominance within entire disease franchises. In multiple sclerosis, for instance, Roche is building a comprehensive portfolio that includes the leading infused therapy (Ocrevus), a next-generation convenient formulation (Ocrevus subcutaneous), and a novel oral therapy in late-stage development (fenebrutinib).5 This multi-pronged approach creates a more resilient and defensible franchise, increasing switching costs for clinicians and making it more difficult for any single competing product to disrupt its leadership.

4. Financial Performance & Growth Analysis

Roche’s financial performance over the past several years reflects a period of significant transition. The company has successfully managed the twin pressures of biosimilar erosion and the post-pandemic normalization of its diagnostics business, with the strength of its new pharmaceutical portfolio driving a return to solid growth. This performance is underpinned by exceptional cash flow generation and a disciplined approach to cost management.

Revenue Growth Trends

An analysis of Roche’s revenue from 2018 to 2024 shows a resilient growth trajectory despite major headwinds. Group sales increased from CHF 56.8 billion in 2018 to a peak of CHF 63.3 billion in 2022, driven by both the new pharma portfolio and pandemic-related diagnostics sales.40 In 2023, sales dipped to CHF 58.7 billion as the COVID-19 testing business declined sharply, before recovering strongly to CHF 60.5 billion in 2024.3

A deeper analysis of the growth at constant exchange rates (CER) reveals the underlying dynamics:

  • Underlying Strength: The core driver of performance is the pharmaceutical base business, which grew by 8% in 2023 and 9% (excluding COVID-related products) in 2024.4 This demonstrates the successful commercial execution for new products like Vabysmo, Ocrevus, Hemlibra, and Phesgo.
  • Managed Headwinds: This strong base growth was powerful enough to absorb two significant negative impacts: the CHF 4.3 billion decline in COVID-19 product sales in 2023 and the persistent biosimilar erosion of legacy drugs, which represented a CHF 1.0 billion headwind in 2024.4
  • Currency Impact: A crucial factor in interpreting Roche’s reported financials is the persistent strength of the Swiss Franc (CHF). As a company that reports in CHF but generates the majority of its sales in other currencies like the U.S. dollar and the Euro, a strengthening franc creates a significant translational headwind. In 2023, this effect was particularly pronounced, turning a 1% sales growth at CER into a 7% decline in reported CHF terms.42 In 2024, the adverse impact on sales was 4 percentage points.43 Therefore, analysis of performance at constant exchange rates provides a more accurate picture of the company’s operational momentum.

Profitability Metrics and Margin Analysis

Roche’s profitability remains robust, with a notable divergence between its “Core” and IFRS (International Financial Reporting Standards) results, which underscores the importance of understanding non-cash accounting charges.

  • Core Operating Profit: This metric, which excludes non-recurring items and amortization of intangible assets, is the company’s preferred measure of underlying performance. Core operating profit grew by a strong 14% (CER) in 2024 to CHF 20.8 billion, driven by higher sales and effective cost management. The corresponding Core Operating Profit Margin expanded from 32.8% in 2023 to 34.4% in 2024, indicating improving operational efficiency.6
  • IFRS Operating Profit: In contrast, IFRS operating profit decreased by 6% (CER) in 2024.6 The primary reason for this divergence was significant non-cash impairment charges against goodwill related to past acquisitions, notably Flatiron Health and Spark Therapeutics.6 These charges reflect a reassessment of the long-term value of these acquired assets rather than a deterioration in current business operations.

Return on Invested Capital (ROIC) and Efficiency

Roche has historically generated very high returns on capital. However, ROIC has been on a declining trend in recent years, falling from a peak of 31.0% in 2020 to 24.1% in 2024.44 This trend is largely attributable to the significant increase in the company’s invested capital base following several large acquisitions. While the returns from these deals are yet to be fully realized, Roche’s ROIC remains at an elite level compared to the broader healthcare sector and most of its pharmaceutical peers, demonstrating continued efficient use of capital.44

Cash Flow Generation and Balance Sheet Strength

Roche is a prolific and consistent generator of cash, which is a cornerstone of its financial strength and strategic flexibility.

  • Cash Flow: In 2024, operating free cash flow surged by 34% (CER) to an impressive CHF 20.1 billion.6 This powerful cash generation comfortably funds the company’s substantial R&D investments, its active M&A strategy, and its consistently growing dividend.
  • Balance Sheet: The company maintains a very strong balance sheet, reflected in its high credit ratings of AA from Standard & Poor’s and Fitch, and Aa2 from Moody’s.42 Net debt stood at CHF 18.7 billion at the end of 2023, having increased due to the cash outlay for the Telavant acquisition, but this level remains highly manageable relative to the company’s earnings and cash flow.42

The following table provides a summary of key financial metrics from 2019 to 2024, illustrating the trends discussed.

Metric (CHF millions)201920202021202220232024
Group Sales61,46658,32362,80163,28158,71660,495
Pharmaceuticals Sales48,51744,53245,04145,55144,61446,171
Diagnostics Sales12,94913,79117,76017,73014,10214,324
Core Operating Profit22,48821,54021,89722,17319,24020,823
IFRS Operating Profit17,54318,50118,15517,47615,39513,417
Core Net Income16,56915,08516,13316,33715,12015,317
IFRS Net Income14,10715,06814,93513,53112,3589,187
Core Diluted EPS (CHF)19.1619.1619.8120.3018.5718.80
Cash Flow from Operations20,95818,14621,89020,41317,29422,127
R&D Investment (Core)11,66412,15213,70814,05313,23713,042
R&D as % of Sales19.0%20.8%21.8%22.2%22.5%21.6%
Data compiled from Roche Annual and Finance Reports for respective years. All figures are in CHF millions unless otherwise noted. Core metrics are non-IFRS measures provided by the company. 1

5. Growth Drivers & Pipeline Assessment

Roche’s long-term growth prospects are intrinsically linked to the productivity of its R&D engine and its ability to successfully commercialize new products. The company is actively managing its pipeline and pursuing external innovation through strategic acquisitions to secure future growth drivers.

R&D Pipeline Strength and Late-Stage Assets

As of early 2025, Roche’s pipeline contained 71 new molecular entities (NMEs) and a total of 122 projects in clinical development or registration.7 The company has recently undertaken a significant portfolio review, terminating approximately 20% of its NME projects since the second quarter of 2023 to sharpen its focus on assets with the highest potential impact.13

The late-stage pipeline (Phase III and registration) contains several promising candidates across key therapeutic areas 39:

  • Oncology:
  • Inavolisib: A selective PI3Kα inhibitor for certain types of advanced breast cancer.
  • Giredestrant: A selective estrogen receptor degrader (SERD) also being investigated for various settings in breast cancer.
  • Divarasib: An inhibitor of the KRAS G12C mutation, a key target in non-small cell lung cancer (NSCLC).
  • Neurology:
  • Fenebrutinib: An oral BTK inhibitor being studied for both relapsing and primary progressive forms of multiple sclerosis, with the potential to complement the market-leading Ocrevus franchise.
  • Prasinezumab: An antibody targeting alpha-synuclein for early-stage Parkinson’s disease, a high-risk but potentially transformative program.
  • Immunology:
  • Afimkibart: A monoclonal antibody targeting TL1A for inflammatory bowel diseases like ulcerative colitis and Crohn’s disease.

Recent Drug Approvals and Commercial Performance

Roche has secured several important regulatory approvals in 2024 that expand the market for its key products:

  • Ocrevus SC: Approval in Europe for a subcutaneous injection of Ocrevus offers a more convenient administration option for MS patients, which is a key strategy to defend its market share.5
  • Alecensa: Approvals in the U.S. and Europe for the adjuvant (early-stage) treatment of ALK-positive lung cancer significantly expand the addressable patient population beyond the advanced disease setting.5
  • Vabysmo: Received approval for an additional indication in retinal vein occlusion, further broadening the reach of this ophthalmology blockbuster.50
  • PiaSky: Approved in the U.S. for paroxysmal nocturnal haemoglobinuria (PNH), a rare blood condition.50

The commercial performance of recent launches has been exceptional. Vabysmo’s trajectory has been particularly strong, rapidly capturing market share from established competitors and exceeding analyst expectations.32 Phesgo and Polivy have also delivered robust growth, contributing significantly to the Pharmaceuticals Division’s overall performance.32

Diagnostic Innovation and New Product Launches

The Diagnostics Division continues to innovate and expand its offerings. In 2024 alone, the division launched 4 new platforms and 21 new tests across its Core Lab, Molecular Lab, and Pathology Lab segments.5 This continuous menu expansion is critical for driving recurring revenue growth from its large installed base of instruments.

Partnership and Acquisition Strategy

In a significant strategic shift, Roche has become more active in M&A since late 2023, executing several key transactions to bolster its pipeline in high-growth areas:

  • Telavant Holdings ($7.1 billion): This acquisition brought in a promising late-stage antibody (RVT-3101, an anti-TL1A) for inflammatory bowel disease, a major immunology market.12
  • Carmot Therapeutics ($2.7 billion): This deal provided Roche with a portfolio of clinical-stage assets for obesity and diabetes, marking a strategic entry into one of the largest and fastest-growing therapeutic markets.52
  • Poseida Therapeutics ($1.0 billion): This acquisition enhances Roche’s capabilities in cell therapy, particularly allogeneic (“off-the-shelf”) CAR-T therapies, a next-generation approach in oncology.52

This disciplined, science-driven approach to M&A is a core component of management’s strategy to supplement internal R&D and secure long-term growth drivers.53

6. Capital Allocation Strategy

Roche’s capital allocation strategy is characterized by a balanced approach that prioritizes reinvestment in the business for long-term growth while providing consistent and growing returns to shareholders. This strategy is enabled by the company’s powerful and predictable cash flow generation.

Dividend Policy and Yield

A cornerstone of Roche’s commitment to shareholder returns is its dividend policy. The company has a long and distinguished track record of increasing its dividend annually.

  • Consecutive Growth: The dividend proposed for the 2023 fiscal year (CHF 9.60 per share) marked the 37th consecutive annual increase.4 For the 2024 fiscal year, the Board of Directors proposed a further 1% increase to CHF 9.70 per share.5
  • Yield: Based on recent trading levels, Roche’s forward dividend yield is approximately 3.6% to 3.8%.55 This attractive yield provides a significant component of total shareholder return and offers a degree of valuation support, particularly for income-focused investors.
  • Payout Ratio: The dividend is well-supported by earnings. The proposed 2023 dividend represented a payout ratio of 51.7% of Core EPS, a sustainable level that allows for both shareholder returns and substantial reinvestment in the business.42 One source indicates a payout ratio of 72.5% based on different earnings calculations.55

Share Buyback Programs

Roche does not typically engage in large, recurring share buyback programs as a primary means of capital return. Instead, it has used buybacks for more strategic purposes.

  • Novartis Stake Repurchase: The most significant recent transaction was the repurchase of 53.3 million shares held by its competitor Novartis in December 2021.57 This was a major strategic move to regain full flexibility and simplify its capital structure. The repurchased shares were subsequently cancelled, which had an accretive effect on earnings per share for the remaining shareholders.57

R&D Investment

The primary use of capital at Roche is reinvestment into its R&D engine to fuel future innovation and growth.

  • Investment Levels: The company consistently allocates a significant portion of its revenue to R&D. In 2023 and 2024, core R&D investments were CHF 13.2 billion and CHF 13.0 billion, respectively, representing approximately 22.5% and 21.6% of group sales.3 This level of investment is among the highest in the industry and is fundamental to sustaining its competitive advantage.

M&A Activity

After a period of relative quiet, Roche has recently re-engaged in significant M&A activity, focusing on strategic, science-driven “bolt-on” acquisitions rather than large-scale mergers. The acquisitions of Telavant, Carmot, and Poseida between late 2023 and early 2025 demonstrate a clear strategy to use its strong balance sheet to acquire promising external innovation in areas of high strategic priority and significant market potential.12

7. Recent Developments & Challenges (2023-2025)

The period from 2023 through 2025 represents a critical phase for Roche, marked by the successful management of major challenges and the strong performance of new growth drivers.

Major Patent Expirations and Biosimilar Impact

The most significant challenge has been the ongoing loss of exclusivity for the company’s former “big three” oncology blockbusters: Avastin, Herceptin, and Rituxan. The impact of biosimilar competition on these products has been substantial and continued through 2023 and 2024. In 2023, combined sales of these three drugs fell by 22%.12 In 2024, the trio, along with other products facing loss of exclusivity, represented a combined sales decline of CHF 1.0 billion.7 The company is now preparing for the next wave of expirations, with key patents for Perjeta and Xolair set to expire in the U.S. in 2025, with potential biosimilar entry in 2026.52

COVID-19 Business Normalization

The sharp decline in demand for COVID-19 tests and treatments was the single largest headwind to growth in 2023. This factor alone accounted for a CHF 4.3 billion reduction in sales compared to 2022.4 The company’s ability to generate positive group-level sales growth at constant exchange rates despite this massive drag was a testament to the strength of its underlying base business. Management has stated that the negative impact from this normalization will be fully washed out by 2025, removing this headwind from future growth comparisons.6

Key Drug Launch Performances

The commercial success of recently launched products has been the most significant positive development.

  • Vabysmo: The launch of this ophthalmology drug has been exceptionally strong, consistently beating analyst expectations and rapidly capturing market share from a well-entrenched competitor. In Q1 2024, sales grew 108% year-over-year.32
  • Phesgo and Polivy: These oncology drugs have also demonstrated very strong growth trajectories, with sales up 81% and 70% respectively in Q1 2024.32

Regulatory and Pipeline Updates

Roche has achieved several positive regulatory milestones, including key approvals for label expansions of Ocrevus (subcutaneous formulation) and Alecensa (early-stage lung cancer).5 However, the pipeline has also faced setbacks. Most notably, the company has discontinued several late-stage clinical trials for its anti-TIGIT immunotherapy, tiragolumab, in various cancer types, reducing the near-term potential of what was once considered a highly promising asset class.10

Management and Strategic Shifts

2023 marked a significant leadership transition as Dr. Thomas Schinecker took over as Group CEO from the long-serving Dr. Severin Schwan, who moved to the role of Chairman.4 Under Schinecker, the company has articulated a clear strategic vision focused on its integrated model and has shown a renewed appetite for strategic, science-driven M&A, as evidenced by the acquisitions of Telavant, Carmot, and Poseida.58 Further management changes are expected in 2025 with the announced retirements of the Head of Pharma Research and Early Development (pRED) and the Head of Group Communications.59

Supply Chain and Manufacturing

Roche has not reported any significant supply chain or manufacturing disruptions. The company is actively managing its global supply chain, including conducting sustainability and human rights audits of its suppliers.60 In a strategic move to optimize its manufacturing network, Roche completed the divestment of its manufacturing facility in Vacaville, California, to Lonza for $1.2 billion in October 2024.52

8. Risk Assessment

An investment in Roche is subject to a range of industry-specific and company-specific risks that must be carefully considered. These include patent cycles, regulatory hurdles, currency fluctuations, and competitive pressures.

Patent Cliff Exposure and Timeline

While Roche has successfully navigated the loss of exclusivity for its major legacy oncology products, the patent cliff remains a persistent risk. The next significant wave of patent expirations is approaching.

  • Perjeta: Basic patents in the U.S. expire in 2025.52
  • Xolair: Formulation patents in the U.S. expire in late 2025.52

    The company anticipates potential biosimilar competition for both products could begin in 2026. These two drugs generated combined U.S. sales of over $4.3 billion in 2024, highlighting the magnitude of the revenue base at risk.52 The long-term patents for current growth drivers like Ocrevus are expected to begin expiring around 2028-2029.61 The company’s ability to defend these franchises through lifecycle management (e.g., Ocrevus SC) and to generate sufficient growth from its pipeline to offset these future losses is a critical long-term risk factor.

Regulatory and Clinical Trial Risks

The development of new drugs is an inherently risky, lengthy, and expensive process. There is no guarantee that molecules in the pipeline will demonstrate sufficient safety and efficacy to gain regulatory approval.

  • Pipeline Setbacks: The recent discontinuation of several late-stage trials for the anti-TIGIT antibody tiragolumab is a clear example of this risk.53 Despite significant investment and initial promise, the asset failed to meet its primary endpoints, leading to a significant pipeline write-down. Any similar failures in other key late-stage programs, such as for fenebrutinib in MS or giredestrant in breast cancer, would negatively impact future growth expectations.

Currency Exposure

As a Swiss company reporting in CHF but earning a majority of its revenue in USD and EUR, Roche has significant exposure to foreign currency fluctuations.

  • Translational Risk: The consistent strength of the Swiss franc has created a significant headwind, depressing reported results in CHF. In 2023, currency effects had an adverse impact of 8 percentage points on sales and 15 percentage points on Core EPS.42 While the company reports results at constant exchange rates (CER) to show underlying performance, the reported CHF figures are what ultimately flow through to the financial statements and impact the valuation in its home currency. The company engages in hedging activities, but these cannot fully mitigate broad, sustained currency movements.

Competitive Threats

Roche faces intense competition on multiple fronts.

  • Innovator Competition: In key areas like oncology and immunology, Roche competes with other large pharma companies that have highly effective drugs and deep R&D pipelines. Merck’s Keytruda, for example, has established a dominant position in many areas of immuno-oncology.
  • Biosimilar Competition: The threat from biosimilars is structural and permanent. As biologic drugs lose patent protection, lower-cost competitors will enter the market, leading to significant and rapid price and volume erosion.
  • Emerging Players: The biopharmaceutical landscape is dynamic, with smaller, more agile biotech companies often at the forefront of scientific innovation. The rise of new technologies like AI could further lower barriers to entry in drug discovery, potentially increasing the number of competitive threats over the long term.18

Dependence on Key Products and Markets

Despite a broad portfolio, Roche’s growth is disproportionately dependent on a handful of key products and one major geographic market.

  • Product Concentration: The continued strong performance of Ocrevus, Vabysmo, and Hemlibra is critical to meeting near-term growth targets. Any unforeseen safety issues, competitive challenges, or pricing pressures on these specific products would have an outsized impact on the company’s overall performance.
  • Geographic Concentration: With over 53% of its pharmaceutical revenue derived from the United States, Roche is highly exposed to the American healthcare system.6

Healthcare Policy and Pricing Pressure Risks

This is arguably one of the most significant long-term risks. Governments and payers worldwide are focused on controlling healthcare costs.

  • U.S. Inflation Reduction Act (IRA): The IRA grants Medicare the authority to negotiate prices for some of the highest-selling drugs. As a supplier of many high-cost specialty medicines, Roche is directly exposed to this legislation. The prospect of direct price negotiation could significantly impact the future profitability of its products in its largest market.15
  • Global Pricing Reforms: Other markets are also implementing cost-containment measures. For example, recent healthcare pricing reforms in China contributed to a 15% decline in Roche’s Diagnostics sales in the Asia-Pacific region in the first half of 2025.9

9. Valuation Analysis

Assessing the valuation of Roche Holding AG requires a multi-faceted approach, considering its current trading multiples relative to historical ranges and peer groups, the intrinsic value of its distinct business segments, and its attractiveness as a dividend-paying investment.

Current Trading Multiples vs. Historical Ranges

An analysis of Roche’s valuation multiples indicates that they are trading within their historical ranges, having compressed from the peaks seen in 2021.

  • Price-to-Earnings (P/E) Ratio: Roche’s TTM P/E ratio stands at approximately 19.0x.62 This is situated between its recent year-end low of 17.6x in 2023 and its high of 26.0x in 2021, suggesting a more moderate valuation compared to recent years.62
  • Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: The company’s TTM EV/EBITDA multiple is approximately 10.7x.63 This is near the bottom of its five-year range, which saw a low of 10.2x in 2023 and a peak of 13.4x in 2021.63 This compression reflects both the market’s concerns over the recent patent cliff and the impact of higher interest rates on long-duration assets.

Peer Group Comparison and Relative Valuation

Compared to its global pharmaceutical peers, Roche’s valuation presents a mixed picture.

  • Peer Group: A relevant peer group for the pharmaceutical business includes large, diversified companies such as Johnson & Johnson, Merck, Pfizer, Novartis, and AstraZeneca.33 For the diagnostics business, peers include Abbott, Danaher, and Siemens Healthineers.36
  • Relative Multiples: Roche’s P/E ratio of ~19-23x (depending on the source) appears higher than that of some peers like Merck (~13x) and Pfizer (~14x) but is more in line with Novartis (~18x).62 This premium can often be justified by Roche’s perceived higher quality, the stability of its diagnostics business, and its strong track record of innovation and dividend growth. Its EV/EBITDA multiple of ~10.7x is comparable to the healthcare sector average and sits in the middle of its peer group, below AstraZeneca (~14.4x) and Novartis (~11.5x) but above Sanofi (~8.8x) and GSK (~7.8x).63

Sum-of-the-Parts (SOTP) Analysis

A SOTP analysis is a particularly relevant valuation methodology for Roche due to its two distinct, large-scale businesses. This approach involves valuing the Pharmaceuticals and Diagnostics divisions separately and then adjusting for corporate costs and net debt.

  • Diagnostics Valuation: This segment, characterized by stable, recurring revenues and moderate growth, could be valued using multiples of MedTech and diagnostics peers. Its predictability and market leadership would likely command a solid valuation.
  • Pharmaceuticals Valuation: This segment, with higher growth potential but also higher risk due to patent cycles and pipeline uncertainty, would be valued against large-cap pharmaceutical peers.
    An SOTP analysis could reveal whether the market is ascribing a “conglomerate discount” to Roche or if it fully appreciates the synergistic value of the integrated model.

Discounted Cash Flow (DCF) Considerations

A DCF valuation would be based on projecting future free cash flows. Key assumptions would include:

  • Revenue Growth: Mid-single-digit growth in the medium term, in line with management’s 2025 guidance.9
  • Margins: Potential for modest margin expansion as the sales mix shifts further towards high-margin new products and the impact of COVID-19 sales dissipates.
  • Terminal Value: A terminal growth rate of 1-2%, reflecting long-term global economic and healthcare spending growth.
    Roche’s very strong and consistent free cash flow generation (CHF 20.1 billion in operating free cash flow in 2024) provides a robust foundation for a DCF analysis.6

Dividend Yield Attractiveness

Roche’s dividend yield provides a key element of valuation support.

  • Current Yield: The forward dividend yield is approximately 3.6-3.8%, a compelling figure in the current market environment.55
  • Relative Value: This yield is attractive compared to many sovereign bond yields and the yields offered by many of its large-cap peers. For income-oriented investors, this consistent and growing dividend provides a tangible return and can create a “floor” for the stock’s valuation, as the yield becomes increasingly attractive if the share price falls. The company’s 37-year history of consecutive dividend increases underscores the Board’s commitment to this aspect of shareholder return.4

10. Strategic Outlook & Key Questions

Looking ahead to 2025 and beyond, Roche’s strategic direction under CEO Thomas Schinecker is focused on leveraging its unique integrated structure to navigate an increasingly complex healthcare landscape. The company’s ability to execute this vision will determine its long-term growth sustainability.

Management’s Strategic Vision and Execution

The strategic vision articulated by CEO Thomas Schinecker centers on three core pillars: preventing, stopping, and curing diseases.67 This vision explicitly leverages the combined strengths of the Pharmaceuticals and Diagnostics divisions. The strategy focuses on disease areas with the highest projected societal burden by 2035: cancer, cardiovascular-metabolic diseases, and neurological diseases.68

Execution of this strategy is evident in recent actions:

  • Disciplined M&A: The acquisitions of Carmot (obesity/cardiovascular-metabolic) and Poseida (cell therapy for cancer) directly align with these stated focus areas.52 Management has emphasized a “disciplined” and “science-driven” approach to deals, aiming to strengthen the pipeline in these key areas.53
  • Pipeline Prioritization: The culling of 20% of NMEs from the pipeline since mid-2023 demonstrates a commitment to focusing resources on assets with the highest potential for transformative impact.13
  • Guidance: Management has confirmed its outlook for 2025, projecting mid-single-digit sales growth and high-single-digit growth in core earnings per share, indicating confidence in the near-term momentum of the business.9

Long-Term Growth Sustainability

The central question for Roche is the sustainability of its growth beyond the current cycle of new products. The strong performance of Vabysmo, Ocrevus, and Hemlibra has successfully bridged the gap left by the last major patent cliff, but these products themselves will face loss of exclusivity towards the end of the decade.

  • The Next Wave: Long-term value creation will depend on the success of the current late-stage pipeline. Assets like fenebrutinib (MS), giredestrant (breast cancer), and the newly acquired programs in immunology (anti-TL1A) and obesity are critical for delivering the next wave of growth.
  • The Obesity Question: The $2.7 billion acquisition of Carmot marks a significant strategic entry into the massive obesity market. The success of this venture will be a key determinant of Roche’s growth profile in the 2030s.

Potential for Portfolio Optimization

While management remains publicly committed to the integrated business model, the question of portfolio optimization is a recurring theme.

  • Divestitures: The sale of the Vacaville manufacturing facility to Lonza shows a willingness to optimize non-core assets.52
  • Spin-off Potential: The idea of a potential spin-off of the Diagnostics division to unlock value is a perennial topic among investors. While there is no indication this is being considered, it remains a long-term strategic option if the market continues to apply a conglomerate discount.

Technology Disruption Threats and Opportunities

Technology, particularly AI and machine learning, presents both a major opportunity and a potential threat.

  • Opportunity: Roche is actively investing in AI to enhance R&D productivity and data analysis.5 Leveraging its vast datasets from both diagnostics and clinical trials could create a significant competitive advantage in identifying new drug targets and personalizing treatments.
  • Threat: AI also has the potential to democratize drug discovery, lowering barriers to entry and enabling smaller, more agile competitors to challenge the dominance of large, established R&D organizations.18

Market Share Defense Strategies

Roche’s strategies for defending its market-leading franchises are becoming increasingly sophisticated.

  • Beyond the Pill: The company is moving beyond selling a single product to creating a comprehensive franchise. In MS, the combination of an infused therapy (Ocrevus), a convenient subcutaneous option (Ocrevus SC), and a potential oral therapy (fenebrutinib) aims to meet the needs of all patient segments, creating a durable ecosystem that is difficult for competitors to penetrate.
  • Proactive Lifecycle Management: The “bio-better” strategy, exemplified by Phesgo, is a key tool to manage the lifecycle of its blockbuster biologics. By proactively transitioning the market to an improved, patent-protected version before biosimilar entry, Roche can mitigate the impact of the patent cliff. The successful execution of these defense strategies will be a critical indicator of the company’s long-term resilience and profitability.

Works cited

  1. Roche Holdings – AnnualReports.com, accessed August 26, 2025, https://www.annualreports.com/Company/roche-holdings
  2. Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises, accessed August 26, 2025, https://www.morningstar.com/stocks/roche-builds-wide-moat-with-dominant-oncology-diagnostics-franchises
  3. Roche’s Annual Report 2023, accessed August 26, 2025, https://www.roche.com/investors/annualreport23
  4. Annual Report 2023 – Roche, accessed August 26, 2025, https://assets.roche.com/f/174029/x/2fb3fece51/roche-global-annual-report-2023.pdf
  5. Roche’s Annual Report 2024, accessed August 26, 2025, https://www.roche.com/investors/annualreport24
  6. [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth, accessed August 26, 2025, https://www.roche.com/media/releases/med-cor-2025-01-30
  7. Investor Update – Roche, accessed August 26, 2025, https://assets.roche.com/f/176343/x/774e29fc44/250130_ir_fy24_en.pdf
  8. Investor Update – Roche, accessed August 26, 2025, https://assets.roche.com/f/176343/x/3e163d97e6/250724_ir_hy.pdf
  9. [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025, accessed August 26, 2025, https://www.roche.com/investors/updates/inv-update-2025-07-24
  10. Roche Reports CHF 60.5 Billion Revenue in 2024 with Focus on Oncology and R&D Adjustments – ECHEMI.com, accessed August 26, 2025, https://www.echemi.com/cms/2235719.html
  11. What are the top-selling drugs of Roche? – Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-roche
  12. Roche Holdings, Inc. Annual Report 2023, accessed August 26, 2025, https://assets.roche.com/f/176343/x/0ef2047502/ar23-roche-holdings-inc.pdf
  13. diagnostics-day-22-05-2024.pdf – Roche, accessed August 26, 2025, https://assets.roche.com/f/176343/x/70a97738d3/diagnostics-day-22-05-2024.pdf
  14. Roche Diagnostics, accessed August 26, 2025, https://www.roche.com/about/business/diagnostics
  15. Next in pharma 2025: The future is now – PwC, accessed August 26, 2025, https://www.pwc.com/us/en/industries/pharma-life-sciences/pharmaceutical-industry-trends.html
  16. Global Life Sciences Industry Trends 2025 – Indegene, accessed August 26, 2025, https://www.indegene.com/what-we-think/reports/global-life-sciences-industry-trends-2025
  17. Breakthroughs or bottlenecks? Pharma industry outlook, trends and strategies for 2025 – ZS, accessed August 26, 2025, https://www.zs.com/insights/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond
  18. How 2025 can be a pivotal year of progress for Biopharma | World …, accessed August 26, 2025, https://www.weforum.org/stories/2025/01/2025-can-be-a-pivotal-year-of-progress-for-pharma/
  19. In-vitro Diagnostics Market Size, Growth Outlook 2025 – 2034, accessed August 26, 2025, https://www.gminsights.com/industry-analysis/in-vitro-diagnostics-market
  20. Clinical Diagnostics Market Size | Industry Report, 2030 – Grand View Research, accessed August 26, 2025, https://www.grandviewresearch.com/industry-analysis/clinical-diagnostics-market
  21. Professional Diagnostics Market Size, Growth Analysis, 2033 – IMARC, accessed August 26, 2025, https://www.imarcgroup.com/professional-diagnostics-market
  22. Diagnostic industry dynamics in life sciences: Growth, challenges, and key trends – West Monroe, accessed August 26, 2025, https://www.westmonroe.com/insights/diagnostic-industry-dynamics-in-life-sciences
  23. Diagnostic Testing Market Size, Share, Trends & Growth Report, 2033 – Nova One Advisor, accessed August 26, 2025, https://www.novaoneadvisor.com/report/diagnostic-testing-market
  24. Analyzing the impact of biosimilars on biologic drug development pipelines, accessed August 26, 2025, https://www.drugpatentwatch.com/blog/analyzing-the-impact-of-biosimilars-on-biologic-drug-development-pipelines/
  25. An inflection point for biosimilars – McKinsey, accessed August 26, 2025, https://www.mckinsey.com/industries/life-sciences/our-insights/an-inflection-point-for-biosimilars
  26. Biosimilars continue to drive market competition and increase savings for seniors | PhRMA, accessed August 26, 2025, https://phrma.org/blog/biosimilars-continue-to-drive-market-competition-and-increase-savings-for-seniors
  27. Diagnostics Division – Roche, accessed August 26, 2025, https://assets.roche.com/f/176343/x/82b7ed78fc/irp20200117.pdf
  28. Top 20 Multiple Sclerosis Drugs Market Analysis and Segment Forecasts To 2030, accessed August 26, 2025, https://www.grandviewresearch.com/market-trends/top-20-multiple-sclerosis-drugs-market
  29. Roche scores with FDA nod for subcutaneous version of MS star Ocrevus – Fierce Pharma, accessed August 26, 2025, https://www.fiercepharma.com/pharma/conveniently-roche-doubles-down-another-sub-q-fda-nod-one-ms-star-ocrevus
  30. The Rise of Next-Gen Hemophilia A Therapies – DelveInsight, accessed August 26, 2025, https://www.delveinsight.com/blog/emerging-hemophilia-a-therapies-beyond-factor-viii
  31. HEMLIBRA: Potential Treatment for Hemophilia A Patients – DelveInsight, accessed August 26, 2025, https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment
  32. Roche’s Vabysmo shows no sign of slowdown after Regeneron and Bayer’s launch of Eylea HD – Fierce Pharma, accessed August 26, 2025, https://www.fiercepharma.com/pharma/roches-vabysmo-shows-no-sign-slowdown-after-regeneron-and-bayers-launch-eylea-hd
  33. Who are the main competitors of Roche? – Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/who-are-the-main-competitors-of-roche
  34. Roche: Business Model, SWOT Analysis, and Competitors 2024 – PitchGrade, accessed August 26, 2025, https://pitchgrade.com/companies/roche
  35. F. Hoffmann-La Roche Ltd (Switzerland) and Danaher (US) are Leading Players in the In Vitro Diagnostics Market – MarketsandMarkets, accessed August 26, 2025, https://www.marketsandmarkets.com/ResearchInsight/ivd-in-vitro-diagnostics-market.asp
  36. Top 15 Roche Diagnostics Competitors and Alternatives in 2025, accessed August 26, 2025, https://www.consainsights.com/company-profile/roche-diagnostics/competitors
  37. Pharma 50: The top pharma companies in the world for 2025, accessed August 26, 2025, https://www.drugdiscoverytrends.com/pharma-50-the-50-largest-pharmaceutical-companies-in-the-world-for-2025/
  38. Top 3 Best-Selling Eye Drugs by Recent Sales Data – Xtalks, accessed August 26, 2025, https://xtalks.com/top-3-best-selling-eye-drugs-by-recent-sales-data-4028/
  39. Product Development Portfolio – Roche, accessed August 26, 2025, https://www.roche.com/solutions/pipeline
  40. Annual Report 2018 – Roche, accessed August 26, 2025, https://www.roche.com/investors/annualreport18.htm
  41. Roche’s Annual Report 2022, accessed August 26, 2025, https://www.roche.com/investors/annualreport22
  42. Finance Report 2023 | Roche, accessed August 26, 2025, https://roche.com/fb23e.pdf
  43. Finance Report 2024 | Roche, accessed August 26, 2025, https://roche.com/fb24e.pdf
  44. Return on Invested Capital For Roche Holding Ltd DRC (RHO6) – Finbox, accessed August 26, 2025, https://finbox.com/DB:RHO6/explorer/roic/
  45. ROIC – Roche Holding AG (SIX:ROG) – Alpha Spread, accessed August 26, 2025, https://www.alphaspread.com/security/six/rog/profitability/ratio/return-on-invested-capital
  46. Finance Report 2022 – Roche, accessed August 26, 2025, https://roche.com/fb22e.pdf
  47. Annual Report 2022 – Roche, accessed August 26, 2025, https://www.roche.com/ar22e.pdf
  48. Roche Holdings, Inc. Annual Report 2020, accessed August 26, 2025, https://www.annualreports.com/HostedData/AnnualReportArchive/r/roche-holdings_2020.pdf
  49. Roche Holdings, Inc. Annual Report 2019, accessed August 26, 2025, https://www.annualreports.com/HostedData/AnnualReportArchive/r/roche-holdings_2019.pdf
  50. Investor Update – Roche, accessed August 26, 2025, https://assets.roche.com/f/176343/x/ca635dfd8b/240725_ir_hy.pdf
  51. Roche Holding AG – Access to Medicine Foundation, accessed August 26, 2025, https://accesstomedicinefoundation.org/company/roche-holding-ag
  52. Roche Holdings, Inc. Annual Report 2024, accessed August 26, 2025, https://assets.roche.com/f/176343/x/af901b6ee1/ar24-roche-holdings-inc.pdf
  53. Roche to Stay ‘Disciplined’ With Deals in 2025 – BioSpace, accessed August 26, 2025, https://www.biospace.com/business/roche-to-stay-disciplined-with-deals-in-2025
  54. Roche Holdings, Inc. Half-Year Report 2025, accessed August 26, 2025, https://assets.roche.com/f/176343/x/00c5f2ad11/rh-hy-2025.pdf
  55. Roche Holding AG ( RO.SW) Dividends – Digrin, accessed August 26, 2025, https://www.digrin.com/stocks/detail/RO.SW/
  56. Roche Holding AG (ROG) Dividends – DividendMax, accessed August 26, 2025, https://www.dividendmax.com/switzerland/six-swiss-exchange/pharmaceuticals-and-biotechnology/roche-holding-ag/dividends
  57. Roche completed the repurchase of Roche shares from Novartis, accessed August 26, 2025, https://www.roche.com/investors/updates/inv-update-2021-12-06c
  58. Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world | BioPharma Dive, accessed August 26, 2025, https://www.biopharmadive.com/news/roche-deals-business-development-zaitra-china-oncology/737531/
  59. Changes to the Roche Enlarged Corporate Executive Committee, accessed August 26, 2025, https://www.roche.com/media/releases/med-cor-2025-06-30
  60. Fighting Against Forced Labour and Child Labour in Supply Chains | Roche, accessed August 26, 2025, https://assets.roche.com/f/173850/x/735ff132c0/roche_canada_faflclsca_report_en.pdf
  61. Multiple Sclerosis Market to Generate Sales of $29.8 Billion by 2030, accessed August 26, 2025, https://drug-dev.com/multiple-sclerosis-market-to-generate-sales-of-29-8-billion-by-2030/
  62. Roche (ROG.SW) – P/E ratio – Companies Market Cap, accessed August 26, 2025, https://companiesmarketcap.com/roche/pe-ratio/
  63. Roche Holding AG Participation (SWX:ROG) EV / EBITDA – Investing.com, accessed August 26, 2025, https://www.investing.com/pro/SWX:ROG/explorer/ev_to_ebitda_ltm
  64. EV / EBITDA For Roche Holding Ltd ADR (RHHB.Y) – Finbox, accessed August 26, 2025, https://finbox.com/OTCPK:RHHB.Y/explorer/ev_to_ebitda_ltm/
  65. Roche Holding AG Bearer Shares (RO) – Morningstar, accessed August 26, 2025, https://www.morningstar.com/stocks/xswx/ro/quote
  66. Roche Holding (SWX:RO) Stock Valuation, Peer Comparison & Price Targets, accessed August 26, 2025, https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-ro/roche-holding-shares/valuation
  67. Our strategy – Roche, accessed August 26, 2025, https://www.roche.com/about/strategy
  68. Investors – Roche, accessed August 26, 2025, https://www.roche.com/investors